The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
MedPage Today on MSN4d
STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery DiseaseCHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million ...
For patients with symptomatic peripheral artery disease and type 2 diabetes, semaglutide use is associated with increased ...
The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
News-Medical.Net on MSN2d
Study finds high rates of undiagnosed and untreated peripheral artery diseaseA new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated, with fewer ...
Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...
A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback